Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

NEW YORK, NY / ACCESS Newswire / November 20, 2025 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership ...

According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to ...

Carrot’s Sprints members will have access to sleep, stress, activity and glucose data from Oura and Dexcom, along with ...

Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Shares of DexCom Inc. DXCM slid 1.03% to $70.33 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 6,791.69 and the ...